Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Viibryd
Vilazodone is an antidepressant medication belonging to the serotonin partial agonist and reuptake inhibitor (SPARI) class. It is primarily used to treat major depressive disorder (MDD) in adults. Vilazodone works by enhancing serotonin activity in the brain, a neurotransmitter involved in mood regulation. It acts as a partial agonist at certain serotonin receptors and inhibits serotonin reuptake, increasing its availability in the synaptic cleft.
For the treatment of major depressive disorder (MDD) in adults.
Increased risk of suicidal thinking and behavior in children, adolescents and young adults (18-24 years of age) taking antidepressants.
Outcome:
Serotonin syndrome
Mechanism:
Increased serotonin levels
Outcome:
Increased bleeding risk
Mechanism:
Additive antiplatelet effects
Outcome:
Reduced vilazodone absorption
Mechanism:
Altered gastrointestinal pH
Most likely new formulation: Extended-release formulation (Year 2025, 70% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that vilazodone will maintain its current FDA approval status for MDD.
Antidepressant, Serotonin Partial Agonist and Reuptake Inhibitor (SPARI)
Benzofuran piperazine